首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage
【24h】

Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage

机译:鲑鱼降钙素涂层微球靶向大鼠肠道区域以实现全身生物利用度:肠内滴注法和口服管饲法之间的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Achieving oral peptide delivery is an elusive challenge. Emulsion-based minispheres of salmon calcitonin (sCT) were synthesized using single multiple pill (SmPill (R)) technology incorporating the permeation enhancers (PEs): sodium taurodeoxycholate (NaTDC), sodium caprate (C-10), or coco-glucoside (CG), or the pH acidifier, citric acid (CA). Minispheres were coated with an outer layer of Eudragit (R) L30 D-55 (designed for jejunal release) or Surelease (R)/Pectin (designed for colonic release). The process was mild and in vitro biological activity of sCT was retained upon release from minispheres stored up to 4 months. In vitro release profiles suggested that sCT was released from minispheres by diffusion through coatings due to swelling of gelatin and the polymeric matrix upon contact with PBS at pH 6.8. X-ray analysis confirmed that coated minispheres dissolved at the intended intestinal region of rats following oral gavage. Uncoated minispheres at a dose of similar to 2000 I.U. sCT/kg were administered to rats by intra-jejunal (i.j.) or intra-colonic (i.c.) instillation and caused hypocalcaemia. Notable sCT absolute bioavailability (F) values were: 5.5% from minispheres containing NaTDC (i.j), 17.3% with CG (i.c.) and 18.2% with C-10 (i.c.). Coated minispheres administered by oral gavage at threefold higher doses also induced hypocalcaemia. A highly competitive F value of 2.7% was obtained for orally-administered sCT-minispheres containing CG (45 mu mol/kg) and coated with Eudragit (R). In conclusion, the SmPill (R) technology is a potential dosage form for several peptides when formulated with PEs and coated for regional delivery. PK data from instillations over-estimates oral bioavailability and poorly predicts rank ordering of formulations. (C) 2016 Elsevier B.V. All rights reserved.
机译:实现口服肽的递送是一项难以捉摸的挑战。鲑鱼降钙素(sCT)的乳剂微球是使用单药丸(SmPill(R))技术与渗透增强剂(PEs)合成的:牛磺脱氧胆酸钠(NaTDC),癸酸钠(C-10)或椰油糖苷CG)或pH酸化剂柠檬酸(CA)。小球体用Eudragit(R)L30 D-55(设计用于空肠释放)或Surelease(R)/果胶(设计用于结肠释放)的外层包衣。该过程是温和的,并且在从长达4个月的微球中释放后,sCT的体外生物学活性得以保留。体外释放曲线表明,由于在与pH 6.8的PBS接触后明胶和聚合物基质溶胀,sCT通过包衣扩散而从微球中释放出来。 X射线分析证实,经口管饲法,包被的小球在大鼠的预期肠道区域溶解。未包被的小球的剂量与2000 I.U.通过空肠内(i.j.)或结肠内(i.c.)滴注将sCT / kg给予大鼠,并引起低钙血症。值得注意的sCT绝对生物利用度(F)值是:含NaTDC(i.j)的微球的5.5%,含CG(i.c.)的17.3%和含C-10(i.c.)的18.2%。口服强饲法给予三倍剂量的带涂层小球也可引起低钙血症。对于含有CG(45μmol/ kg)并用Eudragit(R)包衣的口服sCT-微球,获得了2.7%的高度竞争性F值。总之,SmPill(R)技术与PE一起配制并包被用于局部递送时,是几种肽的潜在剂型。滴注的PK数据高估了口服生物利用度,并且无法很好地预测制剂的等级顺序。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号